Cognitive rehabilitation in post-COVID-19 condition: A study protocol for a randomized controlled trial

Hagen, Bjørn Ingulfsvann; Lerdal, Anners; Søraas, Arne; Landrø, Nils Inge; Bø, Ragnhild; Småstuen, Milada Cvancarova; Becker, Jacqueline; Stubberud, Jan

doi:10.1016/j.cct.2022.106955

Cited by 4 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Efforts are focused on assessing the prevalence and classifying the clinical outcomes by clinical signs [ 44 ]. As neurocognitive and psychiatric sequelae are among the most frequent manifestations of post-COVID-19 syndromes, neurorehabilitation interventions have become major targets of studies and clinical trials [ 45 , 46 ]. Further investigations are required in order to evaluate the significance of individual occurrences, diagnose emergent conditions, and tailor a preventive rehabilitative plan.…”

Section: Discussionmentioning

confidence: 99%

Anti-SARS-CoV-2 IgG Antibody Response in Individuals Infected Post Complete Vaccination: A 6-Month Longitudinal Study in Healthcare Professionals

Baratto,

Maistrello,

Pazienza

et al. 2023

Vaccines

View full text Add to dashboard Cite

Serological assays have been used to evaluate the magnitude of naturally acquired and BNT162b2 vaccine-induced immunity. In order to assess the extent to which the antibody response correlates with infection-mediated protection after vaccination, we investigated the kinetics of anti-SARS-CoV-2-S1 IgG in fully vaccinated healthy individuals who did or did not develop COVID-19 within 8 months after the booster dose. The anti-SARS-CoV-2-S1 receptor-binding, domain-specific IgG titer was assessed in serum samples collected at various intervals from 4 months after the second and 6 months after the third dose. The IgG level decreased 33% within 6 months after the second dose and, one month after the third dose, increased dramatically (>300%) compared with the pre-booster time point. COVID-19 infection within two months after the third dose did not cause significant IgG variation, but later viral infections elicited an IgG response similar to the initial response to the booster. The probability of developing COVID-19 and the severity of symptoms were not related to the antibody titer. Our data indicate that repeated exposure to viral antigens by either vaccination or infection at short-term intervals elicits limited boosting effects and that an IgG titer alone is not associated with the prediction of future infections and their symptomatology.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-SARS-CoV-2 IgG Antibody Response in Individuals Infected Post Complete Vaccination: A 6-Month Longitudinal Study in Healthcare Professionals

Baratto,

Maistrello,

Pazienza

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…Non-pharmacological intervention strategies targeting cognition are important in the cognitive trajectory, since we observed better performance in measures of global cognition and executive attention after participating in stimulation and psychoeducation groups, despite the reduced sample size of this study. As mentioned by Hagen et al, , the management of cognitive symptoms is necessary to improve the quality of life and functionality of patients 15 .…”

Section: Discussionmentioning

confidence: 99%

“…This way, psychoeducation would be a relevant tool for relieving anguish and suffering in this population. Thus, individualized assessment allows referring the patient to a rehabilitation program based on their needs, reducing morbidity and improving their quality of life 15 , 16 .…”

Section: Introductionmentioning

confidence: 99%

Cognitive impairment and neuropsychiatric symptoms among individuals with history of symptomatic SARS-CoV-2 infection: a retrospective longitudinal study

Sousa,

Maranhão,

Braga

2024

Dement. neuropsychol.

View full text Add to dashboard Cite

ABSTRACT. COVID-19 is a multisystem disease caused by the RNA virus (coronavirus 2 or SARS-CoV-2) that can impact cognitive measures. Objective: To identify the main cognitive and neuropsychiatric symptoms in adults who had no cognitive complaints prior to the infection. Specifically, to observe the trajectory of cognitive and neuropsychiatric performance after 6 months. Methods: This is a retrospective longitudinal study. Forty-nine patients (29 reassessed after 6 months), with a positive PCR test, with no prior cognitive complaints that only presented after the infection and without a history of structural, neurodegenerative or psychiatric neurological diseases. A brief cognitive assessment battery (MoCA), the Trail Making Test (TMT-A, B, ∆), and the Verbal Fluency Test were used, as well as the scales (Hospital Anxiety and Depression Scale-HADS, Fatigue Severity Scale-FSS). Correlation tests and group comparison were used for descriptive and inferential statistics. Level of significance of α=5%. Results: Mean age of 50.4 (11.3), 12.7 (2.8) years of education, higher percentage of women (69.8%). No psycho-emotional improvement (depression and anxiety) was observed between the evaluations, and patients maintained the subjective complaint of cognitive changes. The HAD-Anxiety scale showed a significant correlation with TMT-B errors. The subgroup participating in cognitive stimulation and psychoeducation showed improvement in the global cognition measure and the executive attention test. Conclusion: Our results corroborate other studies that found that cognitive dysfunctions in post-COVID-19 patients can persist for months after disease remission, as well as psycho-emotional symptoms, even in individuals with mild infection. Future studies, with an increase in casuistry and control samples, are necessary for greater evidence of these results.

show abstract

“Brain Fog” After COVID-19 Infection: How the Field of Neuropsychology Can Help Clear the Air

Widmann,

Henkel,

Seibert

2024

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Cognitive rehabilitation in post-COVID-19 condition: A study protocol for a randomized controlled trial

Cited by 4 publications

References 55 publications

Anti-SARS-CoV-2 IgG Antibody Response in Individuals Infected Post Complete Vaccination: A 6-Month Longitudinal Study in Healthcare Professionals

Anti-SARS-CoV-2 IgG Antibody Response in Individuals Infected Post Complete Vaccination: A 6-Month Longitudinal Study in Healthcare Professionals

Cognitive impairment and neuropsychiatric symptoms among individuals with history of symptomatic SARS-CoV-2 infection: a retrospective longitudinal study

“Brain Fog” After COVID-19 Infection: How the Field of Neuropsychology Can Help Clear the Air

Contact Info

Product

Resources

About